ROSEN, A Global Investor Firm, Advocates for Ocugen, Inc. Investors to Act Before Key Deadline in Securities Class Action

NEW YORK, April 27, 2024 (GLOBE NEWSWIRE) - The esteemed Rosen Law Firm, internationally recognized for its commitment to investor rights, emphasizes the urgency for investors who acquired OCGN securities to seek legal guidance promptly. This call to action comes in light of an impending critical deadline in a securities class action lawsuit that was initially instituted by the firm against Ocugen, Inc.

Understanding the Importance of the Deadline

Investors who have procured the OCGN stock and incurred losses might have a substantial claim under the securities class action. The upcoming deadline imposes a constraint on the time left for investors to become active participants in the lawsuit. Thus, partnership with capable counsel is vital for representation and to potentially recuperate lost capital.

About Ocugen, Inc.

Ocugen, Inc., stationed in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical entity primarily engaged in developing groundbreaking gene therapies aimed at treating ocular diseases leading to blindness. As the litigation process advances, it remains imperative for investors to stay informed and consider their legal options.

Ocugen, Securities, Deadline